-

Foundation Medicine Launches FoundationReport+™, a New Digital Reporting Experience to Streamline Precision Cancer Care

Innovative and interactive reporting functionality offers healthcare providers additional tools to complement integrated electronic health records and make it easier to review and act on results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced the launch of FoundationReport+, a new interactive digital report to enhance the useability of comprehensive genomic profiling (CGP) results. The digital view of the Foundation Medicine report provides physicians with an adaptable experience to view genomic insights and supports more efficient and streamlined treatment decisions for their patients.

Accessible through the Foundation Medicine online portal, the new digital reporting tool is customizable to each user’s preference and allows healthcare providers to control the depth of information they would like to see within the digital reporting experience. With improved navigation to actionable insights, the interactive functionality improves overall clarity of patients’ results compared to the traditional PDF report. In order to create an optimal user experience, FoundationReport+ will continue evolving to include new features and functionality in the months ahead based on customer feedback.

“Foundation Medicine continuously strives to deliver complex molecular information in a way that is digestible and actionable for clinicians,” says Foundation Medicine Chief Medical Officer Mia Levy, M.D. “We know that healthcare teams in the clinic are busy and looking for increased efficiency – therefore, our new digital report enables a dynamic experience to support a range of workflows and help providers more easily access targeted treatment options for their patient’s unique cancer.”

FoundationReport+’s digital reporting functionality is one of many updates Foundation Medicine is making to increase digital integration, on-the-go access, and connectivity in order to provide customers with the flexibility they need. This launch complements other recent initiatives to integrate Foundation Medicine reporting into electronic medical records with partners including Epic, OncoEMR, Cerner, and more.

“Having easily navigable access to patients’ genomic insights will help remove some of the barriers we as oncologists can face in our efforts to get individuals on the right treatments in an informed and efficient manner,” said Lee Schwartzberg, M.D., Chief of Oncology/Hematology, Renown Health-Pennington Cancer Institute. “Foundation Medicine’s solutions-oriented approach to customer service is paving the way to more accessible precision care for cancer patients.”

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Contacts

Media:
Abigail Alderman, 781-534-3210
newsroom@foundationmedicine.com

Foundation Medicine


Release Summary
FoundationReport+ is a new interactive digital report from Foundation Medicine to enhance the useability of comprehensive genomic profiling results.
Release Versions

Contacts

Media:
Abigail Alderman, 781-534-3210
newsroom@foundationmedicine.com

Social Media Profiles
More News From Foundation Medicine

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Itovebi™ (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant. Itovebi is a therapy developed by Genentech, a member of the Roche group, which is approved for the treatment of adult patients with endocrine-resistant,...

Foundation Medicine and SWOG Clinical Trials Partnerships Announce Strategic Collaboration to Advance Biomarker-Driven Research and Clinical Trials

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, and SWOG Clinical Trials Partnerships (SWOG CTP) today announced a strategic partnership to advance biomarker-driven research and clinical trials, marking the first collaboration of this nature with a diagnostic company. This partnership builds upon Foundation Medicine’s decade-long collaboration with SWOG Cancer Research Network through the Lung Cancer Master Protocol (Lung-MAP) trial, a m...

US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRP...
Back to Newsroom